U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C33H25F6N3O3
Molecular Weight 625.5603
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of APOPTOZOLE

SMILES

COC1=CC=C(C=C1)C2=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N2)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=C(OC)C=C5

InChI

InChIKey=ZIMMTPFXOMAJTQ-UHFFFAOYSA-N
InChI=1S/C33H25F6N3O3/c1-44-26-11-7-20(8-12-26)28-29(21-9-13-27(45-2)14-10-21)42(18-19-3-5-22(6-4-19)30(40)43)31(41-28)23-15-24(32(34,35)36)17-25(16-23)33(37,38)39/h3-17H,18H2,1-2H3,(H2,40,43)

HIDE SMILES / InChI

Molecular Formula C33H25F6N3O3
Molecular Weight 625.5603
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Apoptozole is an imidazole-based molecule, which induces apoptosis in cancer cells and can be investigated for cancer therapy. It was found, that apoptozole inhibits Heat shock proteins: Hsp70 and Hsc70. Further investigations have not found any experimental evidence that apoptozole interacts with HSP70 proteins in a specific and developable manner. Instead, was found, that apoptozole might form aggregates under aqueous conditions which could interact with HSP70 proteins in a non-specific manner, potentially leading to false positives and inconsistent data.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
mice: Apoptozole (Az) enhances antibody production in mice administered with protein antigens. In an initial study aimed at evaluating the effect of Az on the immune response to antigens, C57BL/6 mice which lack an immunoglobulin G2a (IgG2a) gene were intraperitoneally (i.p.) immunized with each of the two immunogenic protein antigens, keyhole limpet hemocyanin (KLH) and ovalbumin (OVA). Various amounts (0–7.55 mg/kg mouse) of Az were then i.p. injected daily five times from 0 to 4 days after antigen immunization.
Route of Administration: Intraperitoneal
In Vitro Use Guide
In order to determine if apoptozole (Az) stimulates production of infammatory cytokines in antigen presenting cells (APCs), RAW264.7 cells, a mouse macrophage cell line, were incubated with 3 μM of Az for 3, 6 and 12 h. The released cytokines were determined by using a multiplex cytokine assay. The results reveal that Az treatment enhances the secretion of tumor necrosis factor-α (TNF-α) and IL-18. Notably, Az treatment induces more secretion of TNF-α from RAW264.7 cells. In addition, the level of TNF-α production was found to be Az dose-dependent. The results suggested, that Az stimulated APCs to produce TNF-α, which subsequently mediated IFN-γ and IL-6 production from other types of immune cells.
Substance Class Chemical
Record UNII
WD0EH16QCD
Record Status Validated (UNII)
Record Version